Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Last trade$956.99
Day change+$4.59 (+0.48%)
Day range$948.25 – $965.57
Volume354,318
Market cap$98.52B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$98.52B
Price / earnings
20.45×
Price / book
2.94×
Price / sales
5.83×
EV / sales
5.77×
EV / EBITDA
18.18×
Profitability
Earnings per share
$46.57
Return on assets
10.85%
Return on equity
14.38%
Dividend yield
0.39%
Liquidity and leverage
Debt / equity
0.08×
Current ratio
3.35×
Quick ratio
2.89×
Cash ratio
0.59×
Cash flow
Price / cash flow
20.33×
Price / free cash flow
25.75×
Free cash flow
$3.83B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for REGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.12B
$4.29B
$3.61B
$3.88B
$3.75B
$3.68B
$3.03B
$3.79B
Cost of revenue
$573.6M
$576.5M
$669.4M
$584.6M
$521.6M
$530.2M
$464.3M
$565.4M
Gross profit
$4.54B
$3.71B
$2.94B
$3.3B
$3.23B
$3.15B
$2.56B
$3.22B
Selling, general and administrative
$677.8M
$662.1M
$647.7M
$775M
$657.8M
$634.2M
$633M
$792.2M
Research and development
$1.82B
$1.76B
$1.65B
$1.64B
$1.56B
$1.43B
$1.34B
$1.43B
Total operating expenses
$2.49B
$2.42B
$2.29B
$2.43B
$2.21B
$2.07B
$1.97B
$2.18B
Operating income
$2.05B
$1.29B
$642.9M
$869.9M
$1.03B
$1.08B
$591.7M
$1.04B
Interest expense
-$10.6M
-$11M
-$12.9M
-$12.2M
-$19.3M
-$3.6M
-$8.7M
-$10.5M
Income before taxes
$2.28B
$1.53B
$831.2M
$1.04B
$1.76B
$1.52B
$905M
$958.1M
Income taxes
$335.4M
$230.9M
$104M
$199.1M
$303.3M
$127.1M
$96.3M
$40.4M
Net income
$1.95B
$1.3B
$727.2M
$844.6M
$1.46B
$1.39B
$808.7M
$917.7M
Net income attributable to common shareholders
$1.95B
$1.3B
$727.2M
$844.6M
$1.46B
$1.39B
$808.7M
$917.7M
EBITDA
$2.17B
$1.42B
$766.1M
$1.01B
$1.16B
$1.21B
$718.6M
$1.17B
Basic earnings per share
$19.16
$12.62
$6.99
$8.20
$14.09
$13.24
$7.58
$8.53
Diluted earnings per share
$18.45
$12.23
$6.75
$7.86
$13.62
$12.81
$7.27
$8.07
Recent news
Company coverage with links to the original publishers.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
First Trust's FBT and Invesco's PBE are compared as primary vehicles for biotech sector exposure. FBT offers lower fees (0.55% vs 0.59%), higher AUM ($3.0B vs $438M), and stronger 1-year returns (35.7% vs 28.1%), while PBE provides dividend income and uses a multi-factor quantitative approach. The choice depends on investor priorities regarding cost, liquidity, and investment strategy.
Regeneron Pharmaceuticals is highlighted as potentially the cheapest major biotech company, trading at approximately 21x trailing earnings with $16 billion in net cash. The company's stock has climbed over 40% in the past year, driven by strong performance from key products like Libtayo and Eylea HD, which posted record sales. With a robust pipeline of 50 candidates and a $1 billion upfront payment from an expanded Sanofi partnership, Regeneron appears well-positioned for future growth.
Kodiak Sciences reported a Q3 2026 loss of $1.05 per share, wider than expected, as R&D expenses rose 15.5% year-over-year. However, the company announced positive phase III DAYBREAK study results for lead candidate Zenkuda and KSI-501, both meeting primary endpoints against Regeneron's Eylea. Kodiak plans to submit a BLA for Zenkuda by year-end and expects KSI-101 data in December 2026.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.94 per share
Declared
Oct 30, 2026
Ex-dividend
Nov 20, 2026
Pay date
Dec 3, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 18, 2026
$0.94
Aug 31, 2026
recurring
May 20, 2026
$0.94
Jun 4, 2026
recurring
Feb 20, 2026
$0.94
Mar 5, 2026
recurring
Nov 20, 2025
$0.88
Dec 5, 2025
recurring
Aug 18, 2025
$0.88
Sep 3, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.